Evidence map›Paper›PMID 29683458›Full record

ArticleJournal of visualized experiments : JoVE2018

Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol.

Elisabeth Naschberger, Daniela Regensburger, Clara Tenkerian, Melanie Langheinrich, Felix B Engel, Carol Geppert, Arndt Hartmann, Robert Grützmann, Vera S Schellerer, Michael Stürzl

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elisabeth NaschbergerDivision of Molecular and Experimental Surgery, Department of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Daniela RegensburgerDivision of Molecular and Experimental Surgery, Department of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Clara TenkerianDivision of Molecular and Experimental Surgery, Department of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Melanie LangheinrichDepartment of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Felix B EngelDivision of Nephropathology, Department of Pathology, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Carol GeppertDepartment of Pathology, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Arndt HartmannDepartment of Pathology, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Robert GrützmannDepartment of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Vera S SchellererDepartment of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg.
Michael StürzlDivision of Molecular and Experimental Surgery, Department of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg; Michael.Stuerzl@uk-erlangen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary cells isolated from human carcinomas are valuable tools to identify pathogenic mechanisms contributing to disease development and progression. In particular, endothelial cells (EC) constituting the inner surface of vessels, directly participate in oxygen delivery, nutrient supply, and removal of waste products to and from tumors, and are thereby prominently involved in the constitution of the tumor microenvironment (TME). Tumor endothelial cells (TECs) can be used as cellular biosensors of the intratumoral microenvironment established by communication between tumor and stromal cells. TECs also serve as targets of therapy. Accordingly, in culture these cells allow studies on mechanisms of response or resistance to anti-angiogenic treatment. Recently, it was found that TECs isolated from human colorectal carcinoma (CRC) exhibit memory-like effects based on the specific TME they were derived from. Moreover, these TECs actively contribute to the establishment of a specific TME by the secretion of different factors. For example, TECs in a prognostically favorable Th1-TME secrete the anti-angiogenic tumor-suppressive factor secreted protein, acidic and rich in cysteine-like 1 (SPARCL1). SPARCL1 regulates vessel homeostasis and inhibits tumor cell proliferation and migration. Hence, cultures of pure, viable TECs isolated from human solid tumors are a valuable tool for functional studies on the role of the vascular system in tumorigenesis. Here, a new up-to-date protocol for the isolation of primary EC from the normal colon as well as CRC is described. The technique is based on mechanical and enzymatic tissue digestion, immunolabeling, and fluorescence activated cell sorting (FACS)-sorting of triple-positive cells (CD31, VE-cadherin, CD105). With this protocol, viable TEC or normal endothelial cell (NEC) cultures could be isolated from colon tissues with a success rate of 62.12% when subjected to FACS-sorting (41 pure EC cultures from 66 tissue samples). Accordingly, this protocol provides a robust approach to isolate human EC cultures from normal colon and CRC.

Indexed as

Cell Culture TechniquesCell ProliferationClinical ProtocolsColonColorectal NeoplasmsEndothelial CellsFibroblastsHumansNeovascularization, PathologicTumor Microenvironment

Identifiers

PMID29683458
PMCPMC5933406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.